Prognostic factors for local control of sarcomas of the soft tissues managed by radiation and surgery.

abstract：:The combination of gemcitabine and docetaxel exhibits good activity in the treatment of advanced breast cancer. Phase II trial response rates using 21- or 28-day schedules have ranged from 36% to 79% in patient populations with varying degrees of pretreatment. In studies of extensively pretreated anthracycline-resista...

journal_title：Seminars in oncology

authors： Fumoleau P

更新日期：2003-04-01 00:00:00

abstract：:Squamous cell cancer of the cervix is a relatively drug-resistant tumor. Therefore, chemotherapy is predominantly reserved for cervical cancer patients with recurrent or refractory disease following surgery and/or radiation therapy or for patients who present with far advanced, incurable disease. Objective responses t...

journal_title：Seminars in oncology

authors： Alberts DS,Garcia DJ

更新日期：1994-08-01 00:00:00

abstract：:The efficacy and toxicity of combination intravenous carboplatin (300 mg/m2) and cyclophosphamide (600 mg/m2) were evaluated in 70 newly diagnosed patients with advanced-stage epithelial ovarian cancer. Cycles were administered at 4-week intervals for a total of six cycles, and treatment was provided on an outpatient ...

journal_title：Seminars in oncology

authors： Teeling M,Hayes Y,Fitzmaurice B,McGing P,Carney DN

更新日期：1992-02-01 00:00:00

abstract：:Almost 125 years after the first documented case, pulmonary metastasectomy is still poorly understood. No other organ is subject to the wide histologic variety of metastatic insults, and this fact has complicated a complete exposition of when pulmonary metastasectomy may be beneficial. Many physicians still consider p...

journal_title：Seminars in oncology

authors： Sternberg DI,Sonett JR

更新日期：2007-06-01 00:00:00

abstract：:In a significant fraction of patients with NHL, disease develops that is resistant to conventional chemotherapy. Experience using high-dose chemotherapy, with or without TBI, and BMT is expanding. Remissions can be achieved in many patients with refractory NHL in particular those patients with tumors that are still ch...

journal_title：Seminars in oncology

authors： Williams SF

更新日期：1990-02-01 00:00:00

abstract：:Recent advances in understanding tumor-specific immunity have introduced new excitement in the clinical development of vaccines for the treatment of cancer. A better understanding of basic immunologic principles has led to a variety of techniques for enhancing tumor-specific immunity through vaccination. Approaches to...

journal_title：Seminars in oncology

authors： Arlen PM,Kaufman HL,DiPaola RS

更新日期：2005-12-01 00:00:00

abstract：:Many cytotoxic therapies are available for patients with metastatic breast cancer, but response rates are low and acquired or de novo resistance is virtually universal. Among the agents that are used in the treatment of pretreated metastatic breast cancer are vinorelbine, gemcitabine, nab-paclitaxel, pemetrexed, plati...

journal_title：Seminars in oncology

authors： Cobleigh MA

更新日期：2011-06-01 00:00:00

abstract：:Cisplatin has been employed in the treatment of non-small-cell lung cancer (NSCLC) since the late 1970s. Current evidence suggests that it may be the most effective single drug for the treatment of NSCLC patients. The overall response rate as a single agent is 21%, though responses are higher in previously untreated p...

journal_title：Seminars in oncology

authors： Bunn PA Jr

更新日期：1989-08-01 00:00:00

abstract：:Patients with advanced colorectal cancer were randomized to receive either fluorouracil (5-FU) 370 mg/m2 IV days 1 to 5 followed by weekly applications of 5-FU 600 mg/m2 or the same doses of 5-FU preceded by folinic acid 200 mg/m2. Because of toxicity, the weekly 5-FU dose in the combination treatment schedule was red...

journal_title：Seminars in oncology

authors： Steinke B,Günther E,Hirschmann WD,Sondern W,Koniczek KH,Wander HE,Natt F,Wagner T,Hinrichs HF,Werdier D

更新日期：1992-04-01 00:00:00

abstract：:Carcinoma of the bladder is the most prevalent cancer in Egypt and in most African countries. At the National Cancer Institute (NCI), Cairo, it constitutes 30.3% of all cancers. The median age at diagnosis is 46 years, with a male preponderance of 5:1. Whether in Egypt or other African countries such as Sudan, Kenya, ...

journal_title：Seminars in oncology

authors： el-Mawla NG,el-Bolkainy MN,Khaled HM

更新日期：2001-04-01 00:00:00

abstract：:From this brief review is should be evident that the hereditary varieties of common cancers are characterized by a high degree of genetic heterogeneity. The specific types of hereditary cancers can be identified by focusing on the histologic types and sites of involvement, not only of the primary neoplasm, but also of...

journal_title：Seminars in oncology

authors： Anderson DE

更新日期：1978-03-01 00:00:00

abstract：:The current oncology practice of treating cancer with aggressive doses of radiation and chemotherapy is potentially disastrous, as response and side effects vary depending on several factors including pharmacogenetics. This study is the first to evaluate esophageal cancer treatment with a pharmacogenetic paradigm and ...

journal_title：Seminars in oncology

authors： Wu X,Lu C,Chiang SS,Ajani JA

更新日期：2005-12-01 00:00:00

abstract：:Traditionally, medical oncology has focused on the active period of diagnosis, treatment and follow-up of cancer patients, and palliative medicine, the pre-terminal and end-of-life phases. Palliative medicine physicians have particular expertise in communication and symptom control, especially, for example, with pain ...

journal_title：Seminars in oncology

authors： Storey DJ,Fallon MT,Smyth JF

更新日期：2011-06-01 00:00:00

abstract：:Lymphoma and myeloma represent an increasingly important cause of morbidity and mortality in the older patient group. Studies to date, while limited, suggest that there may be differences in the underlying biology of the tumor cell of some lymphoid malignancies in younger versus older patients. Significant new data wi...

journal_title：Seminars in oncology

authors： Westin EH,Longo DL

更新日期：2004-04-01 00:00:00

abstract：:Despite cures in early stage (IA-IIB) non-small cell lung cancer (NSCLC), the 5-year survival rate is only 36%-73%. Surgical resection via lobectomy is the treatment of choice in early-stage NSCLC, with the goal being complete anatomic resection of the tumor and mediastinal lymph node evaluation. Newer technologies, i...

journal_title：Seminars in oncology

authors： Padda SK,Burt BM,Trakul N,Wakelee HA

更新日期：2014-02-01 00:00:00

abstract：:The liver is the most common site of metastatic colorectal cancer (CRC) and the status of this organ is an important determinant of overall survival in patients with advanced disease. Complete resection of hepatic CRC metastases can provide a long-term cure for some patients, but the majority of liver metastases are n...

journal_title：Seminars in oncology

authors： Ruan DT,Warren RS

更新日期：2005-02-01 00:00:00

abstract：:Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with limited effective therapeutic options and exceedingly high mortality rates. Currently, cure can only be achieved through resection, however the vast majority of patients present with advanced disease for which upfront surgery is not an option. In...

journal_title：Seminars in oncology

authors： Raufi AG,Manji GA,Chabot JA,Bates SE

更新日期：2019-02-01 00:00:00

abstract：:The EORTC Lung Cancer Working Party investigated the effects of combination therapy with VP-16 (Ve-Pesid) and cisplatin in the treatment of non-small-cell lung cancer (NSCLC). Neither agent alone is recognized as being associated with a high rate of response in NSCLC, but the combination proved beneficial in our hands...

journal_title：Seminars in oncology

authors： Klastersky J

更新日期：1985-03-01 00:00:00

abstract：:The effectiveness of current chemotherapeutic approaches for the treatment of solid tumors has reached a near plateau, suggesting we are nearing the limit of cytoreduction. It is hypothesized that this may be due to "subset effect," and that drugs administered according to responses predicted for particular subgroups ...

journal_title：Seminars in oncology

authors： Paik S

更新日期：2001-06-01 00:00:00

abstract：:Many small cell carcinomas share morphological and physiological characteristics with normal and neoplastic cells of Pearse's APUD series, including pulmonary APUD cells and pulmonary carcinoid tumors. There is very likely more than one type of APUD cell in the lung, and conclusions that small cell carcinomas and carc...

journal_title：Seminars in oncology

authors： Tischler AS

更新日期：1978-09-01 00:00:00

abstract：:One of the new agents intensively studied in the last decade for the treatment of metastatic breast cancer is vinorelbine (Navelbine; Burroughs Wellcome Co, Research Triangle Park, NC; Pierre Fabre Médicament, Paris, France). This vinca alkaloid produces response rates comparable to other single agents in women with m...

journal_title：Seminars in oncology

authors： Abeloff MD

更新日期：1995-04-01 00:00:00

abstract：:Selective aromatase inhibitors cause regression of breast carcinomas by reducing estrogen production via inhibition of the enzyme aromatase (estrogen synthetase). A higher incidence of hormone-dependent breast cancer occurs in postmenopausal women than in younger women. Thus, total estrogen blockade is more likely to ...

journal_title：Seminars in oncology

authors： Brodie AM,Njar VC

更新日期：1996-08-01 00:00:00

abstract：:A large body of work spanning the past decade has identified the molecular chaperone heat shock protein 90 (Hsp90) as a critical modulator of an extensive network of cellular signaling pathways. Many of the processes overseen by Hsp90 are deregulated in tumor cells, including cell cycle control, gene transcription, an...

journal_title：Seminars in oncology

authors： Cullinan SB,Whitesell L

更新日期：2006-08-01 00:00:00

abstract：:Chemotherapy for prostate cancer currently has an established role in the treatment of hormone-refractory prostate cancer. There is strong evidence that combined modality treatment with androgen ablation in addition to radiotherapy provides a benefit above and beyond radiotherapy alone in patients with a poor prognosi...

journal_title：Seminars in oncology

authors： Sandler HM,Narayan S,Smith DC

更新日期：2003-08-01 00:00:00

abstract：:We review the options for the treatment of newly diagnosed myeloma in a patient who is a candidate for autologous stem cell transplantation (ASCT). Bortezomib, lenalidomide, dexamethasone (VRD) has been studied in two randomized trials as first-line therapy. In one of these trials, VRD demonstrated improved overall su...

journal_title：Seminars in oncology

authors： Rajan AM,Rajkumar SV

更新日期：2016-12-01 00:00:00

abstract：:Inhibition of cellular DNA synthesis is the major action of gemcitabine. In cells, this drug is converted to its triphosphate (dFdCTP), which is incorporated into DNA and terminates DNA strand elongation. After incorporation of gemcitabine nucleotide into the DNA strand, one more deoxynucleotide is incorporated, and t...

journal_title：Seminars in oncology

authors： Huang P,Plunkett W

更新日期：1995-08-01 00:00:00

abstract：:Session IV of the Second International Colloquium on Cardio-Oncology held in Kraków, focused on the cardiovascular risks of using hormone replacement therapy in breast cancer and androgen deprivation therapy in prostate cancer and continued the theme from Session 3 with a discussion of risk reduction strategies. The d...

journal_title：Seminars in oncology

authors： Plummer C,Steingart RM,Jurczak W,Iakobishvili Z,Lyon AR,Plastaras JP,Minotti G

更新日期：2019-12-01 00:00:00

abstract：:Immune dysregulation, a hallmark of chronic lymphocytic leukemia (CLL), manifests itself in three autoimmune diseases: warm autoimmune hemolytic anemia (AIHA); idiopathic thrombocytopenia (ITP); and, pure red cell aplasia (PRCA). AIHA occurs in 11% of advanced stage CLL patients. Prednisone is the first treatment of c...

journal_title：Seminars in oncology

authors： Diehl LF,Ketchum LH

更新日期：1998-02-01 00:00:00

abstract：:Pancreatic neoplasms are morphologically and genetically heterogeneous and include a wide variety of tumors ranging from benign to malignant with an extremely poor clinical outcome. Our understanding of these pancreatic neoplasms has improved significantly with recent advances in cancer sequencing. Awareness of molecu...

journal_title：Seminars in oncology

authors： Rishi A,Goggins M,Wood LD,Hruban RH

更新日期：2015-02-01 00:00:00

abstract：:The control of nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy has remained difficult, even with the use of combination antiemetic regimens containing metoclopramide. Although these patients receive a lower daily dose of cisplatin, the emetogenic potential remains high. In addition, many ...

journal_title：Seminars in oncology

authors： Hainsworth JD

更新日期：1992-08-01 00:00:00